Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2003

Leonard JP, Coleman M, Ketas JC, Chadburn A, Ely S, Furman RR, et al. Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma. J Clin Oncol. 2003;21(16):3051-9.

Feldman E, Najfeld V, Schuster M, Roboz G, Chadburn A, Silver RT. The emergence of Ph-, trisomy -8+ cells in patients with chronic myeloid leukemia treated with imatinib mesylate. Exp Hematol. 2003;31(8):702-7.

Fournier E, Isakoff SJ, Ko K, Cardinale CJ, Inghirami GG, Li Z, et al. The B cell SH2/PH domain-containing adaptor Bam32/DAPP1 is required for T cell-independent II antigen responses. Curr Biol. 2003;13(21):1858-66.

Moscat J, Diaz-Meco MT, Rennert P. NF-kappaB activation by protein kinase C isoforms and B-cell function. EMBO Rep. 2003;4(1):31-6.

Larcher B, Arisi E, Berloffa F, Demichelis F, Eccher C, Galligioni E, et al. Analysis of user-satisfaction with the use of a teleconsultation system in oncology. Med Inform Internet Med. 2003;28(2):73-84.

Porcu P, Baiocchi RA, Magro C. Recent developments in the biology and therapy of T-cell and natural killer-cell lymphomas. Curr Opin Oncol. 2003;15(5):353-62.

Magro CM, Allen J, Pope-Harman A, W Waldman J, Moh P, Rothrauff S, et al. The role of microvascular injury in the evolution of idiopathic pulmonary fibrosis. Am J Clin Pathol. 2003;119(4):556-67.

A Crowson N, Brown TJ, Magro CM. Progress in the understanding of the pathology and pathogenesis of cutaneous drug eruptions : implications for management. Am J Clin Dermatol. 2003;4(6):407-28.

Chiarle R, Gong JZ, Guasparri I, Pesci A, Cai J, Liu J, et al. NPM-ALK transgenic mice spontaneously develop T-cell lymphomas and plasma cell tumors. Blood. 2003;101(5):1919-27.

Gotlib V, Darji J, Bloomfield K, Chadburn A, Patel A, Braunschweig I. Eosinophilic variant of chronic myeloid leukemia with vascular complications. Leuk Lymphoma. 2003;44(9):1609-13.